114 related articles for article (PubMed ID: 32571015)
1. Dual Targeting of Norepinephrine Transporter (NET) Function and Thyrointegrin αvβ3 Receptors in the Treatment of Neuroblastoma.
Karakus OO; Godugu K; Rajabi M; Mousa SA
J Med Chem; 2020 Jul; 63(14):7653-7662. PubMed ID: 32571015
[TBL] [Abstract][Full Text] [Related]
2. Discovery of dual targeting PEGylated BG-P
Ozen Karakus O; Godugu K; Mousa SA
Bioorg Med Chem; 2021 Aug; 43():116278. PubMed ID: 34157571
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel bifunctional thyrointegrin antagonists for neuroblastoma.
Karakus OO; Godugu K; Fujioka K; Mousa SA
Bioorg Med Chem; 2021 Jul; 42():116250. PubMed ID: 34118788
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Efficacy and Mechanisms of a Dual Targeting of Norepinephrine Transporter and Thyrointegrin αvβ3 Antagonist in Neuroblastoma.
Godugu K; Karakus OO; Fujioka K; Glinsky GV; Mousa SA
J Cancer; 2022; 13(8):2594-2606. PubMed ID: 35711848
[No Abstract] [Full Text] [Related]
5. Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin α
Rajabi M; Godugu K; Sudha T; Bharali DJ; Mousa SA
Bioconjug Chem; 2019 Dec; 30(12):3087-3097. PubMed ID: 31714064
[TBL] [Abstract][Full Text] [Related]
6. Norepinephrine transporter analog benzylguanidine-conjugated nanoparticles for the delivery of paclitaxel in neuroblastoma.
Karakus OO; Godugu K; Salaheldin T; Fujioka K; Mousa SA
Nanomedicine (Lond); 2021 Nov; 16(26):2331-2342. PubMed ID: 34651508
[No Abstract] [Full Text] [Related]
7. Anti-Cancer Activities of Thyrointegrin α
Godugu K; Rajabi M; Mousa SA
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204997
[TBL] [Abstract][Full Text] [Related]
8. Synergistic active targeting of dually integrin αvβ3/CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies.
Shi S; Zhou M; Li X; Hu M; Li C; Li M; Sheng F; Li Z; Wu G; Luo M; Cui H; Li Z; Fu R; Xiang M; Xu J; Zhang Q; Lu L
J Control Release; 2016 Aug; 235():1-13. PubMed ID: 27235150
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel thyrointegrin αvβ3 antagonist fb-PMT (NP751) in the management of human glioblastoma multiforme.
Godugu K; Hay BA; Glinsky GV; Mousa SA
Neurooncol Adv; 2023; 5(1):vdac180. PubMed ID: 36879662
[TBL] [Abstract][Full Text] [Related]
10. Novel Polyethylene Glycol-Conjugated Triazole Derivative with High Thyrointegrin αvβ3 Affinity in Acute Myeloid Leukemia Management.
Sudha T; Godugu K; Darwish NHE; Nazeer T; Mousa SA
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439224
[TBL] [Abstract][Full Text] [Related]
11. Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol, a Thyrointegrin α
Sudha T; Godugu K; Glinsky GV; Mousa SA
Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453545
[TBL] [Abstract][Full Text] [Related]
12. Novel Meta-iodobenzylguanidine-Based Copper Thiosemicarbazide-1-guanidinomethylbenzyl Anticancer Compounds Targeting Norepinephrine Transporter in Neuroblastoma.
Zhang H; Xie F; Cheng M; Peng F
J Med Chem; 2019 Aug; 62(15):6985-6991. PubMed ID: 31283215
[TBL] [Abstract][Full Text] [Related]
13. Nano Diaminopropane tetrac and integrin αvβ3 expression in different cancer types: Anti-cancer efficacy and Safety.
Godugu K; Sudha T; Davis PJ; Mousa SA
Cancer Treat Res Commun; 2021; 28():100395. PubMed ID: 34034044
[TBL] [Abstract][Full Text] [Related]
14. New Thyrointegrin α
Hay BA; Godugu K; Darwish NHE; Fujioka K; Sudha T; Karakus OO; Mousa SA
J Med Chem; 2021 May; 64(9):6300-6309. PubMed ID: 33886292
[TBL] [Abstract][Full Text] [Related]
15. Nano-Targeting of Thyrointegrin αvβ3 Receptor in Solid Tumors and Impact on Radiosensitization.
Sudha T; Rehman MU; Darwish NHE; Coskun MD; Satti JA; Davis PJ; Mousa SA
Radiat Res; 2021 Oct; 196(4):375-385. PubMed ID: 34260732
[TBL] [Abstract][Full Text] [Related]
16. An octopus-mimic PEGylated peptide as a specific integrin αvβ3 inhibitor for preventing tumor progression.
Shan X; Zhang L; Xu Y; Sun L; Guo L; Feng S; Ge H; Gu T; Ning X
Chem Commun (Camb); 2020 Feb; 56(14):2178-2181. PubMed ID: 31971174
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer.
Rajabi M; Yalcin M; Mousa SA
Bioorg Med Chem Lett; 2018 Apr; 28(7):1223-1227. PubMed ID: 29519736
[TBL] [Abstract][Full Text] [Related]
18. Targeting tachykinin receptors in neuroblastoma.
Henssen AG; Odersky A; Szymansky A; Seiler M; Althoff K; Beckers A; Speleman F; Schäfers S; De Preter K; Astrahanseff K; Struck J; Schramm A; Eggert A; Bergmann A; Schulte JH
Oncotarget; 2017 Jan; 8(1):430-443. PubMed ID: 27888795
[TBL] [Abstract][Full Text] [Related]
19. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Pastorino F; Loi M; Sapra P; Becherini P; Cilli M; Emionite L; Ribatti D; Greenberger LM; Horak ID; Ponzoni M
Clin Cancer Res; 2010 Oct; 16(19):4809-21. PubMed ID: 20702613
[TBL] [Abstract][Full Text] [Related]
20. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
Leblond P; Dewitte A; Le Tinier F; Bal-Mahieu C; Baroncini M; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
Anticancer Drugs; 2013 Sep; 24(8):818-25. PubMed ID: 23728220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
